OncoZenge in brief

OncoZenge is a Swedish pharmaceutical company founded in 2020 originating from a collaboration between Moberg Pharma and leading clinicians from Hvidovre Hospital in Denmark.

Oncozenge develops superior products for cancer supportive care. We focus currently on preparing a phase 3 trial for our lead asset BupiZenge®, following superior results in Phase 2, where pain levels were reduced by 50% compared to Standard of Care.

BupiZenge® can radically improve quality of life for patients with severe oral pain, originating for example from radiation therapy or chemotherapy of cancer.